{"id":"W2110333911","doi":"10.1016/j.ahj.2013.07.012","title":"Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","year":2013,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Abbott Diabetes Care; Novartis Pharma; Abbott Vascular; St. Jude Medical; National Institutes of Health; Genentech; Saint Luke's Health System; ResMed; Novo Nordisk; Dexcom; Amylin Pharmaceuticals; Cleveland Clinic; Leona M. and Harry B. Helmsley Charitable Trust; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Halozyme; Sanofi; Park Nicollet Foundation","keywords":"Medicine; Liraglutide; Myocardial infarction; Diabetes mellitus; Internal medicine; Stroke (engine); Placebo; Clinical endpoint; Type 2 diabetes; Body mass index; Randomized controlled trial; Heart failure; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009062245,0.001890978,0.002759816,0.0004079953,0.0005995884,0.001625244,0.0009871015,0.001985642,0.007587122],"category_scores_gemma":[0.006169843,0.0006417059,0.001564252,0.0004114037,0.001051296,0.001282272,0.001014635,0.002454913,0.001846583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007186651,"about_ca_system_score_gemma":0.001707389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004068049,"about_ca_topic_score_gemma":0.0006800376,"domain_scores_codex":[0.9957085,0.002919818,0.0002246628,0.0005543556,0.0002831517,0.0003096038],"domain_scores_gemma":[0.9979302,0.0004424047,0.0006147886,0.0002037237,0.0002563675,0.0005525041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9730613,0.003457635,0.004061986,0.0009023687,0.001039298,0.00006348723,0.00005521382,0.0003173096,0.00100592,0.0004990803,0.003589161,0.01194719],"study_design_scores_gemma":[0.9590634,0.03290632,0.003238566,0.0001029724,0.0008922839,0.00003688543,0.0000221068,0.0005174658,0.000273201,0.0004916283,0.00243368,0.00002132175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8588142,0.01422847,0.006274697,0.007563372,0.002417713,0.07964965,0.01047064,0.0006045253,0.01997673],"genre_scores_gemma":[0.8610762,0.003019525,0.0109195,0.007953702,0.002094405,0.09941459,0.006406155,0.00008642326,0.009029475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009062245,"threshold_uncertainty_score":0.04792631,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0777163334936535,"score_gpt":0.338293751376686,"score_spread":0.2605774178830326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}